Hepatitis B Vaccine Market Size
The Global Hepatitis B Vaccine Market reached USD 4.3 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 6.1 billion by 2030. The global hepatitis B vaccine market is expected to exhibit a CAGR of 4.6% during the forecast period (2023-2030). Hepatitis B vaccination can protect against the hepatitis B disease. Hepatitis B is a liver disease that can produce a few weeks of moderate sickness or a devastating, permanent condition.
There are two types of heptatitis B involved. Acute hepatitis B treatment is a mild condition that causes fever, exhaustion, lack of appetite, nausea, vomiting, jaundice etc and Chronic hepatitis B is a long-term condition caused by the presence of the hepatitis B virus in the body.
Furthermore, hepatitis B vaccine market size is growing rapidly because of the following factors, rising government initiatives, policies and awareness programs have played a significant role in promoting hepatitis B vaccination, increasing number of hepatitis B infections and deaths, various governments have implemented numerous strategies to increase vaccine coverage including mandating hepatitis B vaccination for infants, children, and high-risk populations will drive the market.
Market Scope
| Metrics | Details |
| CAGR | 4.6% |
| Size Available for Years | 2021-2030 |
| Forecast Period | 2023-2030 |
| Data Availability | Value (US$) |
| Segments Covered | Type, End User, and Region |
| Regions Covered | North America, Europe, Asia-Pacific, South America and Middle East & Africa |
| Fastest Growing Region | Asia-Pacific |
| Largest Region | North America |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Infection Type Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
To Know more Insights - Download Sample
Market Dynamics
The Increasing Demand For Hepatitis B Vaccination
The increasing demand for hepatitis B vaccination is one of the significant driver that helps the market to grow in future. Hepatitis B is a potentially deadly liver infection caused by a virus. Hepatitis B virus (HBV) infection can lead to lifelong infection, cirrhosis, liver cancer, liver failure, and death. Hepatitis B vaccination is available for persons of all ages to prevent HBV infection.
For instance, according to Hepatitis B Foundation, the Hepatitis B Foundation claims, chronic infection affects up to 2.4 million people. Chronic hepatitis B rates are greater in males than females in many nations.
Advanced Research and Development
Increased R&D efforts, clinical trials of hepatitis drugs, an increase in the number of product launches and item endorsements, and the development of new hepatitis drugs for the treatment of various hepatitis types are the main factors driving the growth of the hepatitis B vaccine market. The market is expanding fast as a result of increased joint research activities for successful therapeutic pipeline development.
Furthermore, continuing awareness of hepatitis treatment as a result of collaborations and affiliations in large organisations, as well as the introduction of less approach hepatitis therapy, are boosting market expansion.
The Side Effects Associated with the Hepatitis B Vaccine
Hepatitis B vaccine is safe and effective at preventing hepatitis B infections. The most common side effects are usually mild and last 1-2 days. Severe allergic reactions following vaccination are rare, but can be life threatening. Symptoms of a severe allergic reaction can include hives, swelling of the face and throat, difficulty breathing, a fast heartbeat, dizziness, and weakness.
Market Segment Analysis
The global hepatitis B vaccine is segmented based on type, end user and region.
The Combination Vaccines Type Segment Accounted for Approximately 58.7% of the Hepatitis B Vaccine Share
Combination vaccines type segment with around 58.7% is expected to dominate during the forecast period. Combination vaccinations, often known as multivalent vaccines, incorporate various antigens or immunogens in a single formulation. These vaccinations are intended to protect against numerous illnesses with a single injection, minimising the number of injections required. The combination vaccination also lowers the cost of each vaccine packaging, which contributes to segment market growth.
For instance, on December 2022, Pre Hevbrio, the first vaccination that targets three separate hepatitis B virus (HBV) proteins, has been approved by the Food and Drug Administration. In clinical studies, PreHevbrio provided higher protection than the single-target Engerix-B vaccine, particularly for older individuals and persons with weakened immune systems, and did so more quickly. The new vaccination is licenced for people with any identified HBV subtype.
Market Geographical Share
North America Accounted for Approximately 39.4% of the Market Share in 2022
North America is estimated to hold about 39.4% of the total market share throughout the forecast period. The rising incidence of hepatitis B infections, along with an expanding risk population, particularly newborns and healthcare professionals, is predicted to drive market expansion in the Hepatitis B Vaccine Market.
Increasing R&D spending to improve vaccination effectiveness would minimise the number of doses necessary, greatly expanding market growth. Furthermore, increased government measures to promote vaccination and education campaigns in order to increase vaccine coverage rates would considerably boost the value in the North America area.
For instance, Hepatitis B immunization recommendations were based on a person's risk factors like stigmatising, ineffective, and time-consuming for physicians and patients. Only 30% of persons in the United States are currently immunised against hepatitis B. Acute hepatitis B rates in the United States have gradually climbed over the last decade, particularly among people aged 40 and older. The importance of universal vaccination campaigns in reducing viral morbidity is generally acknowledged.
Market Key Companies
The major global players in the Hepatitis B Vaccine market include Merck & Co., Inc, Sanofi, GlaxoSmithKline plc, Indian Immunologicals Limited, LG Chem, KM Biologics, Dynavax Technologies, Bharat Biotech, Serum Institute of India Pvt. Ltd, and Biological E Limited among others.
COVID-19 Impact
Russia Ukraine Conflict Analysis
The Russia-Ukraine conflict is estimated to have a moderate impact on the global hepatitis B vaccine, owing to the low prevalence and absence of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global hepatitis B vaccine growth over the forecast period.
By Type
- Combination Vaccines
- Single Antigen Vaccine
By End User
- Hospitals
- Clinics
- Vaccination Centre
- Others
By Region
- North America
- The U.S.
- Canada
- Mexico
- Europe
- Germany
- The U.K.
- France
- Spain
- Italy
- Rest of Europe
- South America
- Brazil
- Argentina
- Rest of South America
- Asia-Pacific
- China
- India
- Japan
- Australia
- Rest of Asia-Pacific
- Middle East and Africa
Key Developments
- In December 2022, VBI Vaccines Inc, a biopharmaceutical company driven by immunology in the pursuit of powerful disease prevention and treatment, announced that PreHevbrio 3-antigen Hepatitis B Vaccine (Recombinant) has been approved by Health Canada for active immunization against infection caused by all known subtypes of hepatitis B (HBV) virus in adults 18 years of age and older.
- In February 2023, HEPLISAV B, a two-dose adult Hepatitis B adjuvanted vaccine, has been approved for marketing in the United Kingdom by Dynavax. The United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) has granted Marketing Authorization in Great Britain for HEPLISAV B (Hepatitis B Vaccine (Recombinant), Adjuvanted) for the active immunization against hepatitis B virus infection (HBV) caused by all known subtypes of hepatitis B virus in adults 18 years and older.
- In September 2022, Valneva and VBI have collaborated on a hepatitis B vaccine. Valneva and VBI vaccines have formed a cooperation in key European countries to sell and distribute PreHevbri, Europe's first 3-antigen hepatitis B vaccine.
Why Purchase the Report?
- To visualize the global hepatitis B vaccine market segmentation based on type, end user and region, as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of hepatitis B vaccine market level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global hepatitis B vaccine report would provide approximately 53 tables, 54 figures and 195 pages.
Target Audience 2025
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
